Abbott Laboratories (ABT) is scheduled to announce Q4 earnings results on Thursday, January 22nd, before market open.
The consensus EPS estimate is $1.49 (+11.2% Y/Y) and the consensus revenue estimate is $11.8B (+7.3% Y/Y).
Over the last 2 years, ABT has beaten EPS estimates 88% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 3 upward revisions and 2 downward. Revenue estimates have seen 5 upward revisions and 3 downward.
ABT is rated Hold by Seeking Alpha’s Quant model. The stock demonstrates a mixed performance with stretched valuation, impressive profitability, mixed momentum, and moderate growth, leading to a neutral outlook, the model explains.
Shares of Abbott Laboratories (ABT) have grown 4% over the past year, underperforming the S&P 500’s ~13% total return. The 6-month performance shows a decline of ~2%, suggesting recent challenges.